Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia

The American Urological Association Symptom Index for Benign Prostatic Hyperplasia

Michael J. Barry, Floyd J. Fowler, Michael P. O’Leary et al. · The Journal of Urology · 1992 · 3.4K citations

Medicine, Surgery, Urology +14

EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016

Marko Babjuk, Andreas Böhle, Maximilian Burger et al. · European Urology · 2016 · 2.3K citations

Medicine, Oncology, Urology +16

A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C

Antonio Ojea, José Luís Nogueira, Eduardo Solsona et al. · European Urology · 2007 · 211 citations

Medicine, Oncology, Urology +10

Linguistic validation of the simplified Chinese version of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™)

Sandra A. Mitchell, Natalie Chan, Emily Zhao-Feng Ang et al. · BMC Cancer · 2020 · 168 citations · Full text

Humanities, Oncology, Translation Studies +11

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guérin Instillation Therapy on the Quality of Life in Patients with Nonmuscle Invasive Bladder Cancer: Results of a Prospective, Randomized, Phase II Trial

Paolo Gontero, Marco Oderda, Anja Mehnert et al. · The Journal of Urology · 2013 · 81 citations

Medicine, Oncology, Urology +10